Acoramidis is a high-affinity transthyretin (TTR) stabilizer designed to mimic the structural influence of the protective T119M mutation that inhibits the dissociation of tetrameric TTR.44 In the ATTRibute-CM trial recruiting 632 patients with transthyretin amyloid cardiomyopathy (ATTR-CM), acoramidis (800 mg b.i.d.)significantly improved the four-step primary hierarchical outcome (all-cause mortality, CV-related hospitalization, and change from baseline in NT-proBNP levels and 6MWD). This evidence concerns the gene TTR and cardiac amyloidosis.